Acurx Pharmaceuticals, Inc. Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture
Acurx Pharmaceuticals, Inc. (ACXP) reported Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture of $3.21 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Shareholders' Equity
us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation · last filed 2024-03-15
- Acurx Pharmaceuticals, Inc. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2023-12-31 was $833.28K.
- Acurx Pharmaceuticals, Inc. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2023-09-30 was $833.28K, a 19.56% increase year-over-year.
- Acurx Pharmaceuticals, Inc. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2023-06-30 was $806.49K, a 12.53% increase year-over-year.
- Acurx Pharmaceuticals, Inc. shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2023-03-31 was $733.47K, a 3.63% decline year-over-year.
- Acurx Pharmaceuticals, Inc. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2023 was $3.21M, a 11.66% increase from fiscal 2022.
- Acurx Pharmaceuticals, Inc. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2022 was $2.87M, a 44.29% decline from fiscal 2021.
- Acurx Pharmaceuticals, Inc. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2021 was $5.15M, a 640.80% increase from fiscal 2020.
- Acurx Pharmaceuticals, Inc. shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2020 was $695.83K.
| Period end | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 3 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 6 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 9 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 12 month |
|---|---|---|---|---|
| 2023-12-31 | $833.28K derived: 10-K 12 month − 3 quarters · filed 2024-03-15 | $1.67M derived: sum of 2 quarters · filed 2024-03-15 | $2.47M derived: sum of 3 quarters · filed 2024-03-15 | $3.21M 10-K · filed 2024-03-15 |
| 2023-09-30 | $833.28K 10-Q · filed 2023-11-13 | $1.64M derived: sum of 2 quarters · filed 2023-11-13 | $2.37M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2023-06-30 | $806.49K 10-Q · filed 2023-11-13 | $1.54M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2023-03-31 | $733.47K 10-Q · filed 2023-11-13 | |||
| 2022-12-31 | $2.87M 10-K · filed 2024-03-15 | |||
| 2022-09-30 | $696.97K 10-Q · filed 2023-11-13 | $1.41M derived: sum of 2 quarters · filed 2023-11-13 | $2.17M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $716.68K 10-Q · filed 2023-11-13 | $1.48M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $761.07K 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $5.15M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $2.07M 10-Q · filed 2022-11-10 | $4.29M derived: sum of 2 quarters · filed 2022-11-10 | $4.48M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $2.22M 10-Q · filed 2022-11-10 | $2.41M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $191.67K 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $695.83K 10-K · filed 2022-03-16 | |||
| 2020-09-30 | $175.00K 10-Q · filed 2021-11-12 | $341.67K derived: sum of 2 quarters · filed 2021-11-12 | $508.33K derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | $166.67K 10-Q · filed 2021-11-12 | $333.33K derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2020-03-31 | $166.67K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |